|CHRZASTEK, KLAUDIA - Orise Fellow|
Submitted to: Meeting Abstract
Publication Type: Abstract Only
Publication Acceptance Date: 4/14/2017
Publication Date: N/A
Technical Abstract: Following the 2014-2015 outbreaks of H5N2 and H5N8 (clade 220.127.116.11) highly pathogenic avian influenza (HPAI) in the U.S., studies were performed to identify vaccines with potential to be used as a control mechanism in the event of future outbreaks. We tested both inactivated and recombinant vaccines to determine which demonstrated the best protection in terms of efficacy and reductions in viral shedding after challenge. As expected, the best vaccine was the homologous virus containing the identical hemagglutinin gene found in the HPAI virus, although some less-matched vaccines also provided 100 % protection from clinical disease. Additional studies focused on commercially available vaccines as options for the control of HPAI. In general, the recombinant vaccines provided good protection against poultry-adapted challenge virus. An overview of the results from multiple vaccine-challenge studies with North American lineage H5 HPAI clade 18.104.22.168 will be discussed.